184 related articles for article (PubMed ID: 30769179)
1. Pharmacological urate-lowering approaches in chronic kidney disease.
Li X; Liu J; Ma L; Fu P
Eur J Med Chem; 2019 Mar; 166():186-196. PubMed ID: 30769179
[TBL] [Abstract][Full Text] [Related]
2. Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
Szczurek P; Mosiichuk N; Woliński J; Yatsenko T; Grujic D; Lozinska L; Pieszka M; Święch E; Pierzynowski SG; Goncharova K
PLoS One; 2017; 12(6):e0179195. PubMed ID: 28594873
[TBL] [Abstract][Full Text] [Related]
3. Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
Jeon HJ; Oh J; Shin DH
PLoS One; 2019; 14(6):e0218510. PubMed ID: 31206563
[TBL] [Abstract][Full Text] [Related]
4. Time to target uric acid to retard CKD progression.
Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
[TBL] [Abstract][Full Text] [Related]
5. Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease.
Yano H; Tamura Y; Kobayashi K; Tanemoto M; Uchida S
Clin Exp Nephrol; 2014 Feb; 18(1):50-5. PubMed ID: 23584883
[TBL] [Abstract][Full Text] [Related]
6. Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study.
Yanai H; Katsuyama H; Hakoshima M; Adachi H
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831103
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Hyperuricemia in Chronic Kidney Disease.
Ramirez-Sandoval JC; Madero M
Contrib Nephrol; 2018; 192():135-146. PubMed ID: 29393124
[TBL] [Abstract][Full Text] [Related]
8. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor?
Nashar K; Fried LF
Adv Chronic Kidney Dis; 2012 Nov; 19(6):386-91. PubMed ID: 23089273
[TBL] [Abstract][Full Text] [Related]
9. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.
Nishizawa H; Maeda N; Shimomura I
Hypertens Res; 2022 Apr; 45(4):635-640. PubMed ID: 35046512
[TBL] [Abstract][Full Text] [Related]
10. Salivary uric acid as a noninvasive biomarker for monitoring the efficacy of urate-lowering therapy in a patient with chronic gouty arthropathy.
Zhao J; Huang Y
Clin Chim Acta; 2015 Oct; 450():115-20. PubMed ID: 26276048
[TBL] [Abstract][Full Text] [Related]
11. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis.
Liu X; Zhai T; Ma R; Luo C; Wang H; Liu L
Ren Fail; 2018 Nov; 40(1):289-297. PubMed ID: 29619870
[TBL] [Abstract][Full Text] [Related]
12. Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review.
Tsai CW; Lin SY; Kuo CC; Huang CC
PLoS One; 2017; 12(1):e0170393. PubMed ID: 28107415
[TBL] [Abstract][Full Text] [Related]
13. Serum uric acid and cardio-renal diseases.
Ruilope LM; Pontremoli R
Curr Med Res Opin; 2013 Apr; 29 Suppl 3():25-31. PubMed ID: 23621557
[TBL] [Abstract][Full Text] [Related]
14. Impact of Uric Acid Levels on Kidney Disease Progression.
Rincon-Choles H; Jolly SE; Arrigain S; Konig V; Schold JD; Nakhoul G; Navaneethan SD; Nally JV; Rothberg MB
Am J Nephrol; 2017; 46(4):315-322. PubMed ID: 29032376
[TBL] [Abstract][Full Text] [Related]
15. Association of urinary excretion rates of uric acid with biomarkers of kidney injury in patients with advanced chronic kidney disease.
López Iglesias A; Blanco Pardo M; Rodríguez Magariños C; Pértega S; Sierra Castro D; García Falcón T; Rodríguez-Carmona A; Pérez Fontán M
PLoS One; 2024; 19(6):e0304105. PubMed ID: 38861521
[TBL] [Abstract][Full Text] [Related]
16. Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease.
Waheed Y; Yang F; Sun D
Korean J Intern Med; 2021 Nov; 36(6):1281-1293. PubMed ID: 33045808
[TBL] [Abstract][Full Text] [Related]
17. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease.
Yanai H; Adachi H; Hakoshima M; Katsuyama H
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502127
[TBL] [Abstract][Full Text] [Related]
18. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics.
Terkeltaub R; Bushinsky DA; Becker MA
Arthritis Res Ther; 2006; 8 Suppl 1(Suppl 1):S4. PubMed ID: 16820043
[TBL] [Abstract][Full Text] [Related]
19. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
[TBL] [Abstract][Full Text] [Related]
20. Management of Gout and Hyperuricemia in CKD.
Vargas-Santos AB; Neogi T
Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
